GST P1-1 stroke assay diagnostic data

Proteome and researchers at the University of Geneva reported data from an analysis of blood levels of 29 proteins previously identified as early markers of brain damage associated with stroke showing that glutathione S-transferase P1-1 (GST P1-1) was the most significantly elevated marker in the blood of stroke patients compared to healthy controls (p<0.001). Furthermore, the biomarker was able to accurately predict the time of stroke onset in >50% of early stroke patients. The study analyzed blood levels of the 29 proteins using immunoassays in a prospective cohort of 103 stroke patients and 132 healthy controls. Data were published in PLoS ONE. Proteome said that testing for GST P1-1 on all suspected stroke patients upon hospital admission could result in as many as 5 times more patients being eligible for recombinant tissue plasminogen activator (tPA) treatment for ischemic stroke. According to the company, ischemic stroke can only be treated effectively with tPA if administered within a time frame of up to 4.5 hours after symptoms start in the U.K. and up to 3 hours in the U.S. ...